Manasa Velagapudi

Dr. Manasa Velagapudi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
YAYazan Addasi
Yazan Addasi
ANAnny H. Nguyen
Anny H. Nguyen
ASAhmed Sabri
Ahmed Sabri
FAFaran Ahmad
Faran Ahmad
RRRajani Rangray
Rajani Rangray
MVManasa Velagapudi
Manasa Velagapudi
Gastrointestinal Mucormycosis: A Clinical Review

12 October 2023 in Cureus
Verified
Journal Article
Open access
PDF file
SASanjana Aggarwal
Sanjana Aggarwal
MCMargaret Carrig
Margaret Carrig
AAAhad Azeem
Ahad Azeem
ANAnny Nguyen
Anny Nguyen
SDShannon Devries
Shannon Devries
MYMary Elizabeth Y. Yeh
Mary Elizabeth Y. Yeh
Strongyloidiasis is a helminth infection affecting 613.9 million people annually, mainly in the tropics and subtropics. The reported seroprevalence in the United States is 4% with most of the cases reported in immigrants. Human T-lympho-tropic virus 1 (HTLV-1) infections, hypogammaglobulinemia, immunosuppressant use - particularly steroid use, alcoholism, and malnutrition have been associated with an increased risk of strongyloidiasis. Recently, cases of strongyloidiasis hyperinfection syndrome have been described in coronavirus disease 2019 (COVID-19) patients treated with steroids as well. This brief review discusses the epidemiology, clinical features, management, and prevention of strongyloidiasis including some facts about the infection in pregnancy, transplant recipients, and COVID-19 patients. We conducted an online search using the PubMed, Scopus, and Google Scholar databases. Strongyloidiasis can be asymptomatic or present with mild symptoms. Strongyloides stercoralis is known to cause autoinfection. In immunocompromised individuals, it can present with severe symptoms, hyperinfection, or disseminated disease. Reported mortality in cases of disseminated Strongyloidiasis is 87.1%. Serology and detection of larvae in stool by direct microscopy are the most commonly used methods to diagnose strongyloidiasis. The drug of choice for the treatment is ivermectin. However, the use of ivermectin in human pregnancy is not well studied, and its teratogenic risks are unknown. Proactive screening of strongyloidiasis is necessary in immunocompromised individuals to prevent severe disease.

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Faran AhmadFaran Ahmad
Faran Ahmad
AAArslan Ahmed
Arslan Ahmed
SRSanu S. Rajendraprasad
Sanu S. Rajendraprasad
ALAustin Loranger
Austin Loranger
SGSonia Gupta
Sonia Gupta
DMDouglas Moore
Douglas Moore
Multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) received initial reports regarding patients who had presented delayed and multisystem involvement of the disease, with clinical course resembling multisystem inflammatory syndrome in children (MIS-C). This study introduces a case of MIS-A, where the patient presented 3 weeks after initial COVID-19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by the CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high-dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on treatment modalities and clinical predictors.

29 June 2010 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
KNKalyana C. Nandipati
Kalyana C. Nandipati
HNHrishikesh Nerkar
Hrishikesh Nerkar
JSJames Satterfield
James Satterfield
MVManasa Velagapudi
Manasa Velagapudi
URUsha Ruder
Usha Ruder
KSKae-Jae Sung
Kae-Jae Sung
Sarcomas of the breast constitutes <1% of primary malignant breast tumors. Liposarcoma of the breast represents 3-24% of the primary breast sarcomas. Liposarcoma can arise from pre-existing benign lesions like fibroadenoma or from lipoid tissue in the breast. There are only few cases of liposarcoma of the breast in young females reported in the literature. Liposarcoma of the breast typically involves women with age after 50 years. In this article, we present a young woman with liposarcoma of the breast.

1 February 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SPShiv Patel
Shiv Patel
GTGia Thinh Truong
Gia Thinh Truong
ARAjay Rajan
Ajay Rajan
ZCZachary Creech
Zachary Creech
RWRyan W. Walters
Ryan W. Walters
MVManasa Velagapudi
Manasa Velagapudi
By better understanding the long-term effects of COVID-19 and assessing rehabilitation placement among the patients in our study, we hope to determine the predictors of rehabilitation needs in individuals suffering from the long-term sequelae of COVID-19. A retrospective chart review was performed of adult patients with a positive COVID-19 polymerase chain reaction test among multiple hospitals in a regional health system. The main outcomes measured were discharge disposition, total length of hospital stay, and overall all-cause mortality and readmission rates within 30 and 90 days of discharge. Of the 2502 patients included in the study, we found that 65.2% were discharged to home, while the remaining patients were discharged to home healthcare (33.6%), skilled nursing facilities (31.7%), or long-term acute rehabilitation centers (11.6%). The overall all-cause mortality rate at 30 and 90 days were 2.7% and 4.4%, respectively. The overall all-cause 30-day and 90-day readmission rates were 7.0% and 7.6%, respectively. Younger age and shorter hospitalization stays were the most important predictors of home discharge. Discharge to home was also significantly associated with lower all-cause mortality rates at 30 and 90 days after discharge.

24 November 2021 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
EMElizabeth Mause
Elizabeth Mause
MSMohammad Selim
Mohammad Selim
MVManasa Velagapudi
Manasa Velagapudi
Background: Cefazolin is a first-generation cephalosporin commonly used for skin and soft tissue infections, abdominal and orthopedic surgery prophylaxis, and methicillin-sensitive staph aureus. Cephalosporins as a whole are known potential inducers of hemolytic anemia; however, mechanism of action is primarily autoimmune, and compared to other drugs, cefazolin is the least common. Methods: A rare case report of cefazolin-induced hemolytic anemia “CIHA” and a systematic review of CIHA articles in English literature. Two authors performed review of publications and articles were selected based on inclusion and exclusion criteria. A systematic search of the literature yielded 768 entries with five case reports on cefazolin-induced hemolytic anemia. Case presentation/results: An 80-year-old female with methicillin-sensitive Staphylococcus aureus “MSSA” endocarditis. The patient was started on intravenous “IV” cefazolin that that resulted in hemolytic anemia and eosinophilia. Switching to vancomycin improved hemoglobin level and resolved eosinophilia. Four cefazolin-induced hemolytic anemia case reports and one population-based article with a case reported were analyzed with respect to direct antiglobulin test “DAT” (also known as the direct Coombs test) results, prior penicillin sensitivity, and acute anemia causes exclusion. Conclusions: CIHA is a rare cause of clinically significant anemia. The diagnosis of drug-induced anemia is one of exclusion. It is important to consider DAT results and prior penicillin sensitivity when evaluating a patient for cefazolin-induced hemolytic anemia. However, the frequency of cefazolin use and resultant anemia necessitates early recognition of hemolytic anemia and prompt discontinuation of cefazolin, especially with long-term use.